At Stryker, we’re taking our capabilities beyond our current boundaries and definitions. We’re going deeper into clinical relationships. Expanding our reach across the healthcare landscape. And contributing more completely to patient experiences and outcomes.
All to take our business—and the delivery of innovative solutions for healthcare providers and patients—to the next level.
For Stryker’s complete financials, view our 10-K
|(In millions, except per share amounts)||2009||2010||% Change|
1 Adjusted to exclude a property, plant and equipment impairment charge of $76.6 million net of tax benefit of $46.9 million ($0.19 per share) and a gain on the sale of property, plant and equipment of $13.4 million, net of tax expense of $10.9 million ($0.03 per share) recorded in 2010; income taxes on the repatriation of foreign earnings in 2010 and 2009 (a benefit of $7.4 million ($0.02 per share) and expense of $67.1 million ($0.17 per share) in 2010 and 2009, respectively); and a patent litigation gain of $42.9 million, net of tax expense of $19.6 million ($0.11 per share) and restructuring charges of $48.4 million, net of tax benefit of $18.6 million ($0.12 per share) recorded in 2009.
|Sales||$ 6,723||$ 7,320||8.9|
|Earnings before income taxes||1,624||1,730||6.5|
|Adjusted net earnings1||1,180||1,329||12.6|
|Diluted net earnings per share of common stock:|
|Reported||$ 2.77||$ 3.19||15.2|
|Net cash provided by operating activities||$ 1,461||$ 1,547||5.9|
|Dividends paid per share of common stock||$ 0.50||$ 0.60||20.0|
|Cash and current marketable securities||2,955||4,380||48.2|